On December 4, 2025 AstraZeneca reported its ambition to redefine haematology care with new data from its diverse pipeline and portfolio at the 67th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and Exposition, 6-9 December 2025.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
This year’s ASH (Free ASH Whitepaper) congress will feature the Company’s largest presence to date, with 65 abstracts across eight approved and investigational medicines, including 15 oral presentations.
Key presentations include:
Phase I trial of surovatamig: Updated results at three-year follow up from the ongoing first-in-human trial of surovatamig, a CD19xCD3 T-cell engager, in relapsed/refractory (R/R) follicular lymphoma (FL) (Oral Abstract #1005).
DURGA-1 Phase Ib/II study: Initial data for AZD0120 in patients with R/R multiple myeloma (MM). AZD0120 is an investigational BCMAxCD19 chimeric antigen receptor T-cell (CAR T) therapy (Oral Abstract #269).
ECHO Phase III trial: Results after 50 months of follow up evaluating Calquence (acalabrutinib) plus bendamustine and rituximab in the first-line treatment of mantle cell lymphoma (MCL) (Oral Abstract #885).
ALXN1210-TMA-314 Phase III trial: Additional results from the open-label trial evaluating Ultomiris (ravulizumab) in paediatric patients with haematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) (Oral Abstract #1052).
Anas Younes, Senior Vice President, Haematology R&D and Chief Medical Officer, AstraZeneca, said: "We are advancing a broad pipeline of investigational therapies with the potential to redefine patient care across multiple types of blood cancer. At ASH (Free ASH Whitepaper), we are sharing meaningful progress with early efficacy and safety data for AZD0120, our first cell therapy, in multiple myeloma, and for surovatamig, a novel T-cell engager, in B-cell malignancies."
Christophe Hotermans, Senior Vice President, Head of Global Medical Affairs, Alexion, said: "At ASH (Free ASH Whitepaper), we look forward to demonstrating how pioneering science can drive meaningful advances for people living with rare haematologic conditions. New data on Ultomiris, including Phase III results in paediatric patients with HSCT-TMA, will show clinically meaningful overall survival and improved outcomes, highlighting our ongoing pursuit to realise the full potential of our medicines and their impact on treating rare conditions."
Additional highlights include:
SYRUS Phase I/II trial: Updated safety and efficacy data for surovatamig in adolescent and adult patients with R/R B-cell acute lymphoblastic leukaemia (Abstract #3345)
Phase I trial of surovatamig: Initial efficacy and safety data for surovatamig in R/R diffuse large B-cell lymphoma (Abstract #5514)
AZD0120: Follow-up data from two investigator-initiated trials (IIT) in China evaluating AZD0120 as a first-line therapy in high-risk, newly diagnosed MM (Oral Abstract #258).
TrAVeRse Phase II trial: Preliminary results evaluating Calquence plus venetoclax and rituximab in treatment-naïve MCL patients (Oral Abstract #884).
AMPLIFY Phase III trial: Exploratory analyses supporting the safety and efficacy profile of Calquence in first-line chronic lymphocytic leukaemia, with new subgroup data evaluating the impact of prognostic mutations on clinical outcomes (Poster Abstract #3898).
ALPHA Phase III trial: Sub-analysis of results evaluating Voydeya (danicopan) as add-on to Ultomiris or Soliris (eculizumab) in adults with paroxysmal nocturnal haemoglobinuria (PNH) and clinically significant extravascular haemolysis, including in patients with advanced age (Oral Abstract #949).
Ultomiris: Real-world evidence highlighting the impact of Ultomiris in certain patient subgroups across approved indications, including in pregnant patients (Poster Abstracts #6238 and #4458).
Key presentations during the 67th ASH (Free ASH Whitepaper) Annual Meeting and Exposition
Lead Author
Abstract Title
Presentation Details (ET)
Awan, F et al.
Budget Impact of Fixed Duration Acalabrutinib in Combination with Venetoclax in Previously Untreated Chronic Lymphocytic Leukemia Patients in the United States
Abstract #2627
Poster Abstract Session
Session 902. Health Services and Quality Improvement: Lymphoid Malignancies: Poster I
6 December 2025
5:30 PM – 7:30 PM
Cheah, C et al.
Analysis of predictive factors for POD24 in patients with previously untreated mantle cell lymphoma receiving bendamustine-rituximab with or without acalabrutinib in the Phase 3 ECHO trial
Abstract #3578
Poster Abstract Session
Session 623. Mantle Cell, Follicular, Waldenstrom’s, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster II
7 December 2025
6:00 PM – 8:00 PM
Ghia, P et al.
Impact of prognostic mutations on outcomes with fixed-duration acalabrutinib-venetoclax combinations versus chemoimmunotherapy: An exploratory analysis from AMPLIFY
Abstract #3898
Poster Abstract Session
Session 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster II
7 December 2025
6:00 PM – 8:00 PM
Hawkes, E et al.
Acalabrutinib plus venetoclax and rituximab in patients with treatment-naive (TN) mantle cell lymphoma (MCL): Results from the phase 2 TrAVeRse study
Abstract #884
Oral Abstract Session
Session 623. Mantle Cell, Follicular, Waldenstrom’s, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Single Agent and Combination therapy for MCL
8 December 2025
3:00 PM – 03:15 PM
Hou, J-Z et al.
Real-world incidence of treatment-emergent (TE) cardiovascular (CV) events among chronic lymphocytic (CLL)/small lymphocytic lymphoma (SLL) patients receiving acalabrutinib (acala) or zanubrutinib (zanu) monotherapy
Abstract #4506
Poster Abstract Session
Session 906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Poster II
7 December 2025
6:00 PM – 8:00 PM
Seymour, JF et al.
A post hoc safety analysis of fixed-duration acalabrutinib-venetoclax combinations vs chemoimmunotherapy: Results from the Phase 3 AMPLIFY trial
Abstract #2118
Poster Abstract Session
Session 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster I
6 December 2025
5:30 PM – 7:30 PM
Wang, ML et al.
Time to third-line treatment after bendamustine-rituximab with or without acalabrutinib in patients with previously untreated mantle cell lymphoma: Updated analysis of the phase 3 ECHO trial after 50 months of follow-up
Abstract #885
Oral Abstract Session
Session 623. Mantle Cell, Follicular, Waldenstrom’s, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Single Agent and Combination therapy for MCL
8 December 2025
3:15 PM – 3:30 PM
Ultomiris (ravulizumab)
Schoettler, M et al.
Outcomes in pediatric patients with HSCT-TMA treated with ravulizumab
Abstract #1052
Oral Abstract Session
Session 723. Allogeneic Transplantation: Long-term Follow-up, Complications, and Disease Recurrence: Outcomes, toxicities and late effects
8 December 2025
4:45 PM – 05:00 PM
Chaudhury, S et al.
Organ dysfunction in pediatric patients with HSCT-TMA treated with ravulizumab
Abstract #4266
Poster Abstract Session
Session 723. Allogeneic Transplantation: Long-term Follow-up, Complications, and Disease Recurrence: Poster II
7 December 2025
6:00 PM – 8:00 PM
Sherrard, H et al.
Safety of ravulizumab use in pregnancy: Insights from a global pharmacovigilance analysis
Abstract #4458
Poster Abstract Session
Session 905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: Poster II
7 December 2025
6:00 PM – 8:00 PM
Gandhi, S et al.
Real-world analysis of ravulizumab safety and effectiveness in advanced age patients with paroxysmal nocturnal hemoglobinuria: Insights from the international PNH registry
Abstract #6238
Poster Abstract Session
Session 905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: Poster III
8 December 2025
6:00 PM – 8:00 PM
Fasenra (benralizumab)
Klion et al.
Efficacy and safety of benralizumab in patients with hypereosinophilic syndrome: Results from the Phase 3 natron study
Abstract #79
Oral Abstract Session
Session 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Expanding the Therapeutic and Prognostic Landscape in Myeloproliferative Neoplasms, Mastocytosis and Hypereosinophilic Syndrome
06 December, 2025
9:30 AM – 9:45 AM
Klion et al.
Patient perspectives on the burden of hypereosinophilic syndrome: Results from the Phase 3 natron interview sub-study
Abstract #4465
Poster Presentation
Session 905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: Poster II
07 December, 2025
6:00 PM – 8:00 PM
Voydeya (danicopan)
Kulasekararaj, A et al.
Danicopan add-on therapy demonstrates positive efficacy and safety outcomes in advanced age adults with paroxysmal nocturnal hemoglobinuria and clinically significant extravascular hemolysis: A sub-analysis of the phase 3 ALPHA trial
Abstract #949
Oral Abstract Session
Session 905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: Antithrombotic Roulette: Balancing Risk, Cost, and Care
8 December 2025
2:45 PM – 03:00 PM
Surovatamig
Aldoss, I et al.
Safety and efficacy of surovatamig (AZD0486) in adolescent and adult patients with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL): Updated results from the Phase 1/2 SYRUS study
Abstract #3345
Poster Abstract Session
Session 613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Poster II
7 December 2025
6:00 PM – 8:00 PM
Cheah, C et al.
SOUNDTRACK-B: A Phase 2 single-arm study to evaluate the efficacy and safety of surovatamig (AZD0486) in relapsed or refractory B-cell Non-Hodgkin lymphoma
Abstract #3747 (TiP)
Poster Abstract Session
Session 629. Aggressive Lymphomas, Immunotherapy including Bispecific Antibodies: Poster II
7 December 2025
6:00 PM – 8:00 PM
Hou, JZ et al.
Three-year follow-up of the Phase 1 first-in-human study investigating surovatamig, a novel CD19xCD3 T-cell engager, in patients with relapsed/refractory (R/R) follicular lymphoma (FL)
Abstract #1005
Oral Abstract Session
Session 623. Mantle Cell, Follicular, Waldenstrom’s, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological – Follicular Lymphoma
8 December 2025
5:00 PM – 5:15 PM
Kim, TM et al.
Surovatamig (AZD0486), a CD19xCD3 T-cell engager (TCE), demonstrates high rate of minimal residual disease (MRD)-negative complete responses in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), including in patients who previously progressed on CD20 TCE and CD19 CAR T-cell therapies
Abstract #5514
Poster Abstract Session
Session 629. Aggressive Lymphomas, Immunotherapy including Bispecific Antibodies: Poster III
8 December 2025
6:00 PM – 8:00 PM
AZD0120
Du, J et al.
A dual targeting BCMA and CD19 FasTCAR-T (GC012F/AZD0120) as first-line therapy for newly diagnosed multiple myeloma
Abstract #258
Oral Abstract Session
Session 655. Multiple Myeloma: Cellular Therapies: Clinical Trial Advances in CAR T-Cell Therapy for Multiple Myeloma
6 December 2025
2:15 PM – 2:30 PM
Richard, S et al.
Safety and efficacy of AZD0120, a BCMA/CD19 dual-targeting CAR T-cell therapy, in relapsed/refractory multiple myeloma: Preliminary results from the DURGA-1 Phase 1b/2 study
Abstract #269
Oral Abstract Session
Session 704. Multiple Myeloma: Cellular Therapies: Clinical Trial Advances in CAR T-Cell Therapy for Multiple Myeloma
6 December 2025
3:00 PM – 3:15 PM
Feng, J et al.
One-year follow-up of CD19/BCMA dual-targeting FasTCAR-T GC012F (AZD0120) therapy in patients with refractory systemic lupus erythematosus
Abstract #2384
Poster Abstract Session
Session 704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster I
6 December 2025
5:30 PM – 7:30 PM
Lentzsch, S et al.
ALACRITY: A Phase 1b/2 Study of AZD0120 (BCMA/CD19 CAR-T cell therapy) in Participants with Relapsed or Refractory Light Chain Amyloidosis (AL)
Abstract #8236
ePublication
3 November 2025
AZD4512
Han, H et al.
AZD4512: A novel CD22-directed antibody-drug conjugate for the treatment of b-cell malignancies
Abstract #3296
Poster Abstract Session
Session 605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster II
7 December 2025
6:00 PM – 8:00 PM
(Press release, AstraZeneca, DEC 4, 2025, View Source [SID1234661131])